Education
About Us
Working with TipRanks
Follow Us
Elanco Animal Health (ELAN)
NYSE:ELAN
ELAN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.02 - $18.80
Previous CloseN/A
Volume2.53M
Average Volume (3M)6.55M
Market Cap
$6.29B
Enterprise Value$9.79B
Total Cash (Recent Filing)$468.00M
Total Debt (Recent Filing)$4.32B
Price to Earnings (P/E)16.9
Beta1.44
Next Earnings
Aug 11, 2025EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding496,646,500
10 Day Avg. Volume6,842,336
30 Day Avg. Volume6,549,933
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)0.97
Price to Sales (P/S)0.00
P/FCF Ratio15.31
Enterprise Value/Market Cap1.56
Enterprise Value/Revenue0.55
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda12.17
Forecast
1Y Price Target
$15.13Price Target Upside19.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Elanco Animal Health News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceElanco reported upside 1Q results, with sales of $1,193mn, Adj EBITDA of $276mn and Adj EPS of $0.37 all ahead of expectations.
Market PositionElanco's comment that Quattro took 10% of first-quarter broad spectrum sales is materially ahead of expectations and suggests this could be a blockbuster product in year one.
Product LaunchThe launch of new products like Experior and strong performance in Ruminants are driving increased revenue estimates.
Bears Say
Operational CostsIncreased SG&A investments are expected to offset some of the topline growth, impacting earnings per share estimates.
Pet Health SegmentThere was a slight miss in pet health sales, which remains a key investor focus.
Product Launch RisksIf the Credelio Quattro and Zenrelia launches lag, then there is potential downside to constant-currency EBITDA growth this year.
Ownership Overview
0.95% Insiders
47.49% Mutual Funds
1.16% Other Institutional Investors
35.77% Public Companies and Individual Investors
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $8.02 and its highest was $18.80 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $6.29B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Aug 11, 2025 which is in 79 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on May 07, 2025. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.306 by $0.064.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.21.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 496,646,500 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.37 in its last earnings report, beating expectations of $0.306. Following the earnings report the stock price went up 26.288%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in ELAN
Elanco Animal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.13 (19.42% Upside)
$15.13 (19.42% Upside)
Blogger Sentiment
Bullish
ELAN Sentiment 60%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 291.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $483.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.16%
12-Months-Change
Fundamentals
Return on Equity
6.01%
Trailing 12-Months
Asset Growth
-7.69%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Elanco delivered a strong first quarter, exceeding guidance in key areas and driving growth through innovation and strategic initiatives. Despite challenges in U.S. retail and tariffs, the company demonstrated resilience and proactive management, resulting in a positive outlook for the rest of the year.Read More>ELAN Stock 12 Month Forecast
Average Price Target
$15.13
▲( 19.42% Upside)